GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Net Interest Income (for Banks)

CASI Pharmaceuticals (FRA:ENM) Net Interest Income (for Banks)


View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


CASI Pharmaceuticals (FRA:ENM) Business Description

Traded in Other Exchanges
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.